Trial Profile
A Phase 1b/2 Trial to Evaluate the Safety and Efficacy of Radium-223 Dichloride (BAY88-8223) in Combination With Bortezomib and Dexamethasone in Early Relapsed Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Radium 223 chloride (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer
- 25 Feb 2020 Status changed from completed to discontinued.
- 12 Apr 2019 Status changed from active, no longer recruiting to completed.
- 19 Dec 2018 Planned End Date changed from 3 Jan 2022 to 27 Aug 2019.